Literature DB >> 20668480

Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.

Marshall E Kadin, Eric C Vonderheid.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668480     DOI: 10.1038/nrclinonc.2010.105

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN: 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  9 in total

1.  Degree of CD25 expression in T-cell lymphoma is dependent on tissue site: implications for targeted therapy.

Authors:  Dan Jones; Sherif Ibrahim; Kaushali Patel; Rajyalakshmi Luthra; Madeleine Duvic; L Jeffrey Medeiros
Journal:  Clin Cancer Res       Date:  2004-08-15       Impact factor: 12.531

2.  Stress-induced enhancement of skin immune function: A role for gamma interferon.

Authors:  F S Dhabhar; A R Satoskar; H Bluethmann; J R David; B S McEwen
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma.

Authors:  Rakhshandra Talpur; Daniel M Jones; Alvaro J Alencar; Narin Apisarnthanarax; Kelly L Herne; Ying Yang; Madeleine Duvic
Journal:  J Invest Dermatol       Date:  2006-03       Impact factor: 8.551

4.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

5.  Phase III placebo-controlled trial of denileukin diftitox for patients with cutaneous T-cell lymphoma.

Authors:  H Miles Prince; Madeleine Duvic; Ann Martin; Wolfram Sterry; Chalid Assaf; Yijun Sun; David Straus; Mark Acosta; Andres Negro-Vilar
Journal:  J Clin Oncol       Date:  2010-03-08       Impact factor: 44.544

6.  A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma.

Authors:  M Duvic; E A Olsen; G A Omura; J C Maize; E C Vonderheid; C A Elmets; J L Shupack; M F Demierre; T M Kuzel; D Y Sanders
Journal:  J Am Acad Dermatol       Date:  2001-06       Impact factor: 11.527

7.  FOXP3+ regulatory T cells in cutaneous T-cell lymphomas: association with disease stage and survival.

Authors:  L M Gjerdrum; A Woetmann; N Odum; C M Burton; K Rossen; G L Skovgaard; L P Ryder; E Ralfkiaer
Journal:  Leukemia       Date:  2007-08-23       Impact factor: 11.528

Review 8.  Denileukin diftitox: a novel immunotoxin.

Authors:  George Manoukian; Fred Hagemeister
Journal:  Expert Opin Biol Ther       Date:  2009-11       Impact factor: 4.388

Review 9.  Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines.

Authors:  Jens Ruter; Brian G Barnett; Ilona Kryczek; Michael J Brumlik; Benjamin J Daniel; George Coukos; Weiping Zou; Tyler J Curiel
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
  9 in total
  10 in total

1.  Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL).

Authors:  Ulrik Ralfkiaer; Peter H Hagedorn; Nannie Bangsgaard; Marianne B Løvendorf; Charlotte B Ahler; Lars Svensson; Katharina L Kopp; Marie T Vennegaard; Britt Lauenborg; John R Zibert; Thorbjørn Krejsgaard; Charlotte M Bonefeld; Rolf Søkilde; Lise M Gjerdrum; Tord Labuda; Anne-Merete Mathiesen; Kirsten Grønbæk; Mariusz A Wasik; Malgorzata Sokolowska-Wojdylo; Catherine Queille-Roussel; Robert Gniadecki; Elisabeth Ralfkiaer; Carsten Geisler; Thomas Litman; Anders Woetmann; Christian Glue; Mads A Røpke; Lone Skov; Niels Odum
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

Review 2.  Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers.

Authors:  Thomas J Ow; Vlad C Sandulache; Heath D Skinner; Jeffrey N Myers
Journal:  Cancer       Date:  2013-08-20       Impact factor: 6.860

Review 3.  Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components.

Authors:  Franco Dosio; Paola Brusa; Luigi Cattel
Journal:  Toxins (Basel)       Date:  2011-07-14       Impact factor: 4.546

Review 4.  A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.

Authors:  John E Weldon; Ira Pastan
Journal:  FEBS J       Date:  2011-06-02       Impact factor: 5.622

Review 5.  Fallen angels or risen apes? A tale of the intricate complexities of imbalanced immune responses in the pathogenesis and progression of immune-mediated and viral cancers.

Authors:  Beatrice Omusiro Ondondo
Journal:  Front Immunol       Date:  2014-03-06       Impact factor: 7.561

Review 6.  Classification of current anticancer immunotherapies.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; José-Manuel Bravo-San Pedro; Aitziber Buqué; Laura Senovilla; Elisa Elena Baracco; Norma Bloy; Francesca Castoldi; Jean-Pierre Abastado; Patrizia Agostinis; Ron N Apte; Fernando Aranda; Maha Ayyoub; Philipp Beckhove; Jean-Yves Blay; Laura Bracci; Anne Caignard; Chiara Castelli; Federica Cavallo; Estaban Celis; Vincenzo Cerundolo; Aled Clayton; Mario P Colombo; Lisa Coussens; Madhav V Dhodapkar; Alexander M Eggermont; Douglas T Fearon; Wolf H Fridman; Jitka Fučíková; Dmitry I Gabrilovich; Jérôme Galon; Abhishek Garg; François Ghiringhelli; Giuseppe Giaccone; Eli Gilboa; Sacha Gnjatic; Axel Hoos; Anne Hosmalin; Dirk Jäger; Pawel Kalinski; Klas Kärre; Oliver Kepp; Rolf Kiessling; John M Kirkwood; Eva Klein; Alexander Knuth; Claire E Lewis; Roland Liblau; Michael T Lotze; Enrico Lugli; Jean-Pierre Mach; Fabrizio Mattei; Domenico Mavilio; Ignacio Melero; Cornelis J Melief; Elizabeth A Mittendorf; Lorenzo Moretta; Adekunke Odunsi; Hideho Okada; Anna Karolina Palucka; Marcus E Peter; Kenneth J Pienta; Angel Porgador; George C Prendergast; Gabriel A Rabinovich; Nicholas P Restifo; Naiyer Rizvi; Catherine Sautès-Fridman; Hans Schreiber; Barbara Seliger; Hiroshi Shiku; Bruno Silva-Santos; Mark J Smyth; Daniel E Speiser; Radek Spisek; Pramod K Srivastava; James E Talmadge; Eric Tartour; Sjoerd H Van Der Burg; Benoît J Van Den Eynde; Richard Vile; Hermann Wagner; Jeffrey S Weber; Theresa L Whiteside; Jedd D Wolchok; Laurence Zitvogel; Weiping Zou; Guido Kroemer
Journal:  Oncotarget       Date:  2014-12-30

Review 7.  Reactivation of dormant anti-tumor immunity - a clinical perspective of therapeutic immune checkpoint modulation.

Authors:  Richard Greil; Evelyn Hutterer; Tanja Nicole Hartmann; Lisa Pleyer
Journal:  Cell Commun Signal       Date:  2017-01-19       Impact factor: 5.712

8.  Potential role for microRNA-16 (miR-16) and microRNA-93 (miR-93) in diagnosis and prediction of disease progression in mycosis fungoides in Egyptian patients.

Authors:  Iman Mamdouh Talaat; Rania ElSaied Abdelmaksoud; Maha Guimei; Naglaa Fathi Agamia; Ahmed Nugud; Ahmed Taher El-Serafi
Journal:  PLoS One       Date:  2019-10-24       Impact factor: 3.240

Review 9.  Topical and Systemic Formulation Options for Cutaneous T Cell Lymphomas.

Authors:  Taku Fujimura; Ryo Amagai; Yumi Kambayashi; Setsuya Aiba
Journal:  Pharmaceutics       Date:  2021-02-02       Impact factor: 6.321

10.  Successful Treatment of Primary Cutaneous Anaplastic Large Cell Lymphoma with Denileukin Diftitox.

Authors:  Mayuko Amagai; Sadanori Furudate; Kentaro Ohuchi; Toshiya Takahashi; Emi Yamazaki; Hiromu Chiba; Yoshihide Asano; Taku Fujimura
Journal:  Case Rep Oncol       Date:  2022-08-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.